Date published: 2026-1-23

1-800-457-3801

SCBT Portrait Logo
Seach Input

MLN 4924 (CAS 905579-51-3)

0.0(0)
Write a reviewAsk a question

See product citations (1)

CAS Number:
905579-51-3
Molecular Weight:
443.52
Molecular Formula:
C21H25N5O4S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.

QUICK LINKS

MLN 4924 is a small molecule inhibitor of the NEDD8-activating enzyme (NAE). This enzyme is responsible for activating the ubiquitin-proteasome system, which is responsible for the degradation of proteins. MLN 4924 has been studied extensively in laboratory applications and has demonstrated significant anti-tumor activity. It has inhibited the growth of a variety of human cancer cell lines, including those of lung, breast, and ovarian cancer. In addition, it may act to have anti-angiogenic activity, which means that it can inhibit the growth of new blood vessels that are necessary for the growth of tumors.


MLN 4924 (CAS 905579-51-3) References

  1. Neddylation, a novel paradigm in liver cancer.  |  Delgado, TC., et al. 2018. Transl Gastroenterol Hepatol. 3: 37. PMID: 30050997
  2. Suppression of autophagy during mitosis via CUL4-RING ubiquitin ligases-mediated WIPI2 polyubiquitination and proteasomal degradation.  |  Lu, G., et al. 2019. Autophagy. 15: 1917-1934. PMID: 30898011
  3. [New therapeutic agents for acute myeloid leukemia].  |  Hosono, N. 2019. Rinsho Ketsueki. 60: 1108-1119. PMID: 31597834
  4. Neddylation-Independent Activities of MLN4924.  |  Mao, H. and Sun, Y. 2020. Adv Exp Med Biol. 1217: 363-372. PMID: 31898238
  5. Reactivation of Epstein-Barr Virus by HIF-1α Requires p53.  |  Kraus, RJ., et al. 2020. J Virol. 94: PMID: 32641480
  6. E1 Enzymes as Therapeutic Targets in Cancer.  |  Barghout, SH. and Schimmer, AD. 2021. Pharmacol Rev. 73: 1-58. PMID: 33177128
  7. Randomized phase 2 trial of pevonedistat plus azacitidine versus azacitidine for higher-risk MDS/CMML or low-blast AML.  |  Sekeres, MA., et al. 2021. Leukemia. 35: 2119-2124. PMID: 33483617
  8. Current Therapy of the Patients with MDS: Walking towards Personalized Therapy.  |  Palacios-Berraquero, ML. and Alfonso-Piérola, A. 2021. J Clin Med. 10: PMID: 34068316
  9. Advances in myelodysplastic syndrome.  |  Santini, V. 2021. Curr Opin Oncol. 33: 681-686. PMID: 34474438
  10. The NEDD8-activating enzyme inhibitor MLN4924 reduces ischemic brain injury in mice.  |  Yu, H., et al. 2022. Proc Natl Acad Sci U S A. 119: PMID: 35101976
  11. SKP2 drives the sensitivity to neddylation inhibitors and cisplatin in malignant pleural mesothelioma.  |  Salaroglio, IC., et al. 2022. J Exp Clin Cancer Res. 41: 75. PMID: 35197103
  12. Targeting NAE1-mediated protein hyper-NEDDylation halts cholangiocarcinogenesis and impacts on tumor-stroma crosstalk in experimental models.  |  Olaizola, P., et al. 2022. J Hepatol. 77: 177-190. PMID: 35217064
  13. Autophagy Agents in Clinical Trials for Cancer Therapy: A Brief Review.  |  Mohsen, S., et al. 2022. Curr Oncol. 29: 1695-1708. PMID: 35323341
  14. Pevonedistat plus azacitidine vs azacitidine alone in higher-risk MDS/chronic myelomonocytic leukemia or low-blast-percentage AML.  |  Adès, L., et al. 2022. Blood Adv. 6: 5132-5145. PMID: 35728048
  15. A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer.  |  Xu, T., et al. 2022. Signal Transduct Target Ther. 7: 354. PMID: 36253371

Ordering Information

Product NameCatalog #UNITPriceQtyFAVORITES

MLN 4924, 1 mg

sc-484814
1 mg
$286.00